Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Net Margin (2016 - 2022)

Aptevo Therapeutics' Net Margin history spans 8 years, with the latest figure at 5.72% for Q1 2022.

  • For Q1 2022, Net Margin fell 1138.0% year-over-year to 5.72%; the TTM value through Dec 2022 reached 32.53%, up 2479.0%, while the annual FY2022 figure was 32.53%, 2479.0% up from the prior year.
  • Net Margin for Q1 2022 was 5.72% at Aptevo Therapeutics, down from 8.87% in the prior quarter.
  • Across five years, Net Margin topped out at 47.16% in Q3 2019 and bottomed at 616.81% in Q4 2020.
  • The 5-year median for Net Margin is 1.96% (2018), against an average of 42.13%.
  • The largest annual shift saw Net Margin plummeted -58232bps in 2020 before it skyrocketed 62568bps in 2021.
  • A 5-year view of Net Margin shows it stood at 0.67% in 2018, then plummeted by -5251bps to 34.49% in 2019, then plummeted by -1688bps to 616.81% in 2020, then skyrocketed by 101bps to 8.87% in 2021, then tumbled by -36bps to 5.72% in 2022.
  • Per Business Quant, the three most recent readings for APVO's Net Margin are 5.72% (Q1 2022), 8.87% (Q4 2021), and 2.58% (Q3 2021).